The principle is that by accurately monitoring and managing a patient’s haemodynamic status, the risk of complications is minimised. This means longer life, shorter hospital stay and reduced cost of care.

Deltex’s robust evidence base has been established over many years. It is a compelling story of clinical benefit and cost-effectiveness that is helping the company to achieve system-wide adoption of this unique medical technology.

Deltex Medical has been awarded a NICE recommendation for the CardioQ-ODM. ODM Fluid Management is one of the six High Impact Innovations, based on comprehensive evidence which proves that ODM Fluid Management can reduce postoperative complications and reduce length of hospital stay.

TrueVue HD-ICG Brochure